Notably, two MEK inhibitors (PD0325901 and Trametinib) were effective in eliminating ovarian cancer cells in combination with JQ1 (Figure 2D), consistent with our observation that JQ1 treatment activated MAPK targets EGR1 and FOS. Here, EGR1 is linked to ovarian cancer.